KENYA—The Kenya BioVax Institute Limited has signed a Memorandum of Understanding with Hayat Biotech of the UAE.

Biovax manufactures, packages and commercialize specialized health products and technologies including vaccines, therapeutics and other biomedical products.

This MoU signing was witnessed by President Ruto between Dr. Michael Lusiola, the Managing Director of Biovax and Hayat Biotech Mr Naser Al Yammh,  CEO of Hayat Biotech UAE at State House Kenya, Nairobi.

Others who were present in the ceremony were Principal Secretary for Medical Services, Harry Kimtai and the UAE Ambassador to Kenya, HE Dr. Salim Alnaqbi.

The discussion focused on potential collaboration between Hayat Biotech UAE and Kenya BioVax Institute in vaccine manufacturing and research within Kenya and the East African Community (EAC).

The MoU encompassed areas for strengthening scientific research capacity in local research on human vaccines.

This move will facilitate building capacity for producing human vaccines as a long-term measure to ensure Kenya becomes self-sufficient in its vaccine needs and in building security of supply.

It also aligns with the government’s Bottom-Up Economic Transformation Agenda, which seeks to increase Kenya’s capability for vaccine research, development, and manufacturing.

Hayat Biotech has cutting-edge biotechnology facilities in Abu Dhabi and Belgrade, Serbia, with a total yearly manufacturing capacity of 230 million vials.

Its commitment to medical science has established it as a dependable partner for biopharma companies seeking to conduct clinical trials and launch novel products onto the market.

It also serves as a key hub for biopharma research, development, and manufacturing.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.